<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6665">
  <stage>Registered</stage>
  <submitdate>16/03/2017</submitdate>
  <approvaldate>16/03/2017</approvaldate>
  <nctid>NCT03093714</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>FDL169-2015-04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - FDL169
Treatment: drugs - Placebo

Experimental: FDL 169 test formulation (Dose Level 1) - Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects

Experimental: FDL 169 test formulation (Dose Level 2) - Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects

Experimental: FDL 169 test formulation ( Dose Level 3) - Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects

Placebo Comparator: Placebo - Multiple dose placebo as repeat doses in CF subjects


Treatment: drugs: FDL169
CFTR corrector

Treatment: drugs: Placebo
Placebo for FDL169

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Treatment-Emergent Adverse Events - Safety and tolerability of FDL169 as determined by the incidence of adverse events (AEs) and serious adverse events (SAEs).</outcome>
      <timepoint>28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic parameters, Cmax - The pharmacokinetic parameters of FDL169: maximal plasma concentration (Cmax).</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic parameters, Tmax - The pharmacokinetic parameters of FDL169: maximal concentration (Tmax).</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic parameters, AUC - The pharmacokinetic parameters of FDL169: area under the plasma concentration curve (AUC).</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic parameters, CL/F - The pharmacokinetic parameters of FDL169: clearance (CL/F).</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic parameters, V/F - The pharmacokinetic parameters of FDL169: apparent volume of distribution (V/F).</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female subjects with a confirmed diagnosis of CF defined as a sweat chloride
             value =60 mmol/L by quantitative pilocarpine iontophoresis or two CF-causing
             mutations,documented in the subject's medical record or confirmed at screening.

          -  Age 18 and above on the date of informed consent.

          -  Weight =40 kg.

          -  Homozygous for the F508del-CFTR mutation. Genotyping to be confirmed at screening.

          -  Ability to perform a valid, reproducible spirometry test with demonstration of a
             forced expiratory volume in 1 sec (FEV1) &gt;40% of predicted normal for age, sex and
             height.

          -  Screening laboratory tests with no clinically significant abnormalities that would
             interfere with the study assessments (as judged by the Investigator).

          -  Subjects who are sexually active must agree to follow the study's contraception
             requirements.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  An acute upper or lower respiratory tract infection, pulmonary exacerbation, or
             changes in therapy for pulmonary disease within 4 weeks prior to Day 1.

          -  Major complications of lung disease (including massive hemoptysis, pneumothorax, or
             pleural effusion) within 8 weeks prior to screening.

          -  Impaired renal function or known portal hypertension.

          -  History of prolonged QT and/or QTcF (Fridericia's correction) interval (&gt;450 msec) or
             QTcF &gt;450 msec at Screening.

          -  History of solid organ or hematological transplantation.

          -  History of alcohol abuse or drug addiction (including cannabis, cocaine and opiates)
             during the past year, (as judged by the Investigator).

          -  Use of ivacaftor or lumacaftor, within 4 weeks of Day 1

          -  Any change (initiation, change in type of drug, dose modification, schedule
             modification, interruption, discontinuation, or re-initiation) in a chronic
             treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks prior
             to Day 1.

          -  Ongoing immunosuppressive therapy (including systemic corticosteroids).

          -  Hemoglobin &lt;10 g/dL.

          -  Abnormal liver function, at screening.

          -  Abnormal renal function at screening.

          -  Ongoing participation in another clinical study or prior participation without
             appropriate washout (minimum of 10 half- lives or 30 days, whichever is longer) prior
             to Screening visit.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>23/08/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QueenlandQLD</recruitmentstate>
    <hospital>Mater Misericordiae Ltd - South Brisbane</hospital>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>4032 - Chermside</postcode>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Flatley Discovery Lab LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multicenter, randomized, placebo-controlled, dose-escalation study. Enrollment is
      planned to occur at approximately 14 global sites. Approximately 24 subjects with CF.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03093714</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Claudia Ordonez, MD</name>
      <address>Flatley Discovery Lab</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Jingwen Chai</name>
      <address />
      <phone>617-242-0720</phone>
      <fax />
      <email>jingwen.chai@flatleydiscoverylab.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>